Monzr M. Al Malki, M.D.

(877) 460-4673
Monzr M. Al Malki, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Leukemia and Myelodysplastic Syndrome
Research Area
  • Acute Leukemia and MDS/MPN
  • Alternative Donor Transplant (mismatched Related, Unrelated and Cord Blood)
  • Expanding Access to Transplant in Older Patients and Minorities
  • Acute Graft Versus Host Disease Prevention Methods Including in Vivo and Ex Vivo T Cell Depletion
  • Acute Graft Versus Host Disease Treatment
Other Languages Spoken
Arabic
Academic Appointments
  • Professor, Department of Hematology & Hematopoietic Cell Transplantation
  • Director, Unrelated Donor BMT Program
  • Director, Haploidentical Transplant Program
  • Medical Director, City of Hope Histocompatibility (HLA) & Immunogenetics Laboratory
Clinical Teams
Hematology & Hematopoietic Cell Transplantation

Hematologist/oncologist Monzr M. Al Malki, M.D., is a professor professor in the Department of Hematology & Hematopoietic Cell Transplantation, director of the unrelated donor bone marrow transplant and haploidentical transplant programs at City of Hope.

Dr. Al Malki is a physician-scientist with a research focus on mismatched related and unrelated donors as sources of stem cells for transplantation to treat patients with blood cancers without access to matched donors. His research focuses mainly on improving access to transplantation in older patients, minorities and patients with refractory blood cancers. He has ongoing studies to improve the safety of mismatched grafts by in-vivo or ex-vivo T cell depletion.

Dr. Al Malki graduated from the Damascus University School of Medicine, Syria in 2003. He continued his education at Cleveland Clinic’s Huron Hospital, completing his internship and residency in internal medicine. He then went on to earn two fellowships — the first in hematology and medical oncology at Boston University School of Medicine Program at Roger William Medical Center in Providence, Rhode Island, and the latter here at City of Hope in hematopoietic stem cell transplantation. 

Board-certified in internal medicine, hematology and medical oncology, Dr. Al Malki holds memberships with several professional societies including the American College of Physicians, the American Society of Hematology and the American Society of Clinical Oncology. He is also serving as an inspector-trainee for FACT (Foundation for the Accreditation of Cellular Therapy).

Dr. Al Malki has served as a postdoctoral research fellow at Massachusetts General Hospital and Harvard Medical School in Boston. He has written several publications and has been invited to do presentations and poster sessions to discuss his work. 

Location

Education & Experience

Board Certifications

  • Hematology and Medical Oncology, American Board of Internal Medicine

Degrees

  • 2003, M.D., Damascus University School of Medicine, Damascus, Syria
  • 1996-1998, Aleppo University School of Medicine, Aleppo, Syria

Fellowship

  • 2014-2015, Hematopoietic Stem Cell Transplantation Fellow, City of Hope, Duarte, CA
  • 2011-2014, Hematology and Clinical Oncology Fellow, Roger Williams Medical Center, Boston University School of Medicine, Providence, RI
  • 2003, Postdoctoral Research Fellow, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Residency

  • 2006-2008, Medical Resident, Internal Medicine Department, Cleveland Clinic, Huron Hospital, East Cleveland, OH

Internship

  • 2005-2006, Internal Medicine Internship, Cleveland Clinic, Huron Hospital, East Cleveland, OH

Professional Experience

  • 2020-present, Associate Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2019-present, Director, Matched Unrelated Donor Bone Marrow Transplant Program, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2019-present, Director, Bone Marrow Program, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2017-present, Director, Haploidentical Transplant Program, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2015-2020, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2008-2011, Attending Physician, Department of Internal Medicine, Our Lady of Fatima Hospital, St. Joseph Health Services of RI, North Providence, RI

Awards & Memberships

Awards

  • 2023, Graduate Medical Education Excellence in Teaching Award Hematopoietic Cell Transplantation & Cellular Therapy, City of Hope Medical Center

  • 2022, Graduate Medical Education Excellence in Teaching Award Hematopoietic Cell Transplantation, City of Hope Medical Center

  • 2022, Colleague Award, Department of Hematology/Hematopoietic Cell Transplantation & Cellular Therapy, City of Hope Medical Center

  • 2017, Doctor of Nursing Practice Physician Mentor of the Year, Western University of Health Sciences

  • 2017, Scholar of the ISCT-ASBMT Cell Therapy Training Course, ISCT-ASBMT

  • 2015, Methodology in Clinical Investigation Course Completion, City of Hope Clinical Research Training Office

  • 2014, MD Anderson University of Texas at Houston Travel Grant Away, Society of Hematological Malignancy (SOHO 2014)

Memberships

  • 2017, European Society for Blood and Marrow Transplantation

  • 2014, American Society for Blood and Marrow Transplantation

  • 2011, American Society of Clinical Oncology

  • 2011, American Society of Hematology

  • 2005, American College of Physicians

Publications

  • Al Malki, M. M., London, K., Baez, J., Akahoshi, Y., Hogan, W. J., Etra, A., Choe, H., Hexner, E., Langston, A., Abhyankar, S., Ponce, D. M., DeFilipp, Z., Kitko, C. L., Adekola, K., Reshef, R., Ayuk, F., Capellini, A., Chanswangphuwana, C., Eder, M., Eng, G., … Levine, J. E. (2023). Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease. Blood advances, 7(17), 5189–5198. https://doi.org/10.1182/bloodadvances.2023009853
  • Arslan, S., & Al Malki, M. M. (2022). New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT). Hematology. American Society of Hematology. Education Program, 2022(1), 74–82. https://doi.org/10.1182/hematology.2022000398
  • Ciurea, S. O., Kothari, A., Sana, S., & Al Malki, M. M. (2023). The mythological chimera and new era of relapse prediction post-transplant. Blood reviews, 57, 100997. https://doi.org/10.1016/j.blre.2022.100997
  • Al Malki, M. M., Palmer, J., Tsai, N. C., Mokhtari, S., Hui, S., Tsai, W., Aldoss, I., Ali, H., Aribi, A., Cao, T., Mei, M., Sandhu, K. S., Siddiqi, T., Forman, S. J., Nakamura, R., Marcucci, G., Stein, A., Wong, J. Y. C., & Rosenthal, J. (2022). Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood advances, 6(14), 4098–4106. https://doi.org/10.1182/bloodadvances.2022007264
  • Yao, J. M., Yang, D., Clark, M. C., Otoukesh, S., Cao, T., Ali, H., Arslan, S., Aldoss, I., Artz, A., Amanam, I., Salhotra, A., Pullarkat, V., Sandhu, K., Stein, A., Marcucci, G., Forman, S. J., Nakamura, R., & Al Malki, M. M. (2022). Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone marrow transplantation, 57(2), 232–242. https://doi.org/10.1038/s41409-021-01528-y
  • Carter, M., Taniguchi, M., Yang, D., Arslan, S., Shouse, G., Ali, H., Karras, N., Gendzekhadze, K., & Al Malki, M. M. (2022). Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. Bone marrow transplantation, 57(1), 134–136. https://doi.org/10.1038/s41409-021-01494-5
  • Ali, H., Ngo, D., Aribi, A., Arslan, S., Dadwal, S., Marcucci, G., Nakamura, R., Forman, S. J., Chen, J., & Al Malki, M. M. (2021). Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. Transplantation and cellular therapy, 27(11), 938.e1–938.e6. https://doi.org/10.1016/j.jtct.2021.07.008
  • Al Malki, M. M., Tsai, N. C., Palmer, J., Mokhtari, S., Tsai, W., Cao, T., Ali, H., Salhotra, A., Arslan, S., Aldoss, I., Karras, N., Karanes, C., Zain, J., Khaled, S., Stein, A., Snyder, D., Marcucci, G., Forman, S. J., & Nakamura, R. (2021). Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood advances, 5(12), 2650–2659. https://doi.org/10.1182/bloodadvances.2021004192
  • Malki, M. M. A., Song, J. Y., Yang, D., Cao, T., Aldoss, I., Mokhtari, S., Dadwal, S., Marcucci, G., Karanes, C., Snyder, D., Nademanee, A., Forman, S. J., Nakamura, R., & Pullarkat, V. (2020). Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(9), 1697–1703. https://doi.org/10.1016/j.bbmt.2020.06.002
  • Al Malki, M. M., Yang, D., Labopin, M., Afanasyev, B., Angelucci, E., Bashey, A., Socié, G., Karduss-Urueta, A., Helbig, G., Bornhauser, M., Niittyvuopio, R., Ganser, A., Ciceri, F., Brecht, A., Koc, Y., Bejanyan, N., Ferraro, F., Kebriaei, P., Mokhtari, S., Ghobadi, A., … Nagler, A. (2020). Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood advances, 4(9), 2073–2083. https://doi.org/10.1182/bloodadvances.2020001499
  • Dholaria B, Malki MMA, Artz A, Savani BN. Securing the graft during pandemic: are we ready for cryopreservation for all? Biol Blood Marrow Transplant. 2020 Jul;26(7):e145-e146. doi: 10.1016/j.bbmt.2020.04.009. Epub 2020 Apr 17. PMID: 32305358; PMCID: PMC7162777.
  • M.M.A. Malki, K. Gendzekhadze, D. Yang, S. Mokhtari, P. Parker, C. Karanes, J. Palmer, D. Snyder, S.J. Forman, A. Nademanee, R. Nakamura, Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis : Impact of HLA Mismatch, Transplantation. 104 (2020) 1070–1080.
  • Malki MMA, Song JY, Yang D, Cao T, Aldoss I, Mokhtari S, Dadwal S, Marcucci G, Karanes C, Snyder D, Nademanee A, Forman SJ, Nakamura R, Pullarkat V. Iron Overload is Associated with Delayed Engraftment and Increased Non-Relapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Jun 10:S1083-8791(20)30349-9. doi: 10.1016/j.bbmt.2020.06.002. Epub ahead of print. PMID: 32534103.
  • Al Malki MM, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A, Socié G, Karduss-Urueta A, Helbig G, Bornhauser M, Niittyvuopio R, Ganser A, Ciceri F, Brecht A, Koc Y, Bejanyan N, Ferraro F, Kebriaei P, Mokhtari S, Ghobadi A, Nakamura R, Forman SJ, Champlin R, Mohty M, Ciurea SO, Nagler A. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv. 2020 May 12;4(9):2073-2083. doi: 10.1182/bloodadvances.2020001499. PMID: 32396617; PMCID: PMC7218425..
  • Malki, MA., Gupta, R., Jamal, F., Yang, D., Chendri, C., Aldoss, I., Salhotra, A., Dobrin, S., Tran, M., Venkataraman, K., Palmer, J., Stein, AS., Sandhu, K., Khaled, S., Aribi, A., Marcucci, G., Forman, SJ., Snyder, D., Nakamura, R., Ali, H., Pullarkat, V. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplant (2019) doi:10.1038/s41409-019-0741-8
  • Malki, M.M.A., Gendzekhadze, K., Stiller, T. Mokhtari, S., Karanes, C., Snyder, D., Forman, SJ., Nakamura, R., Nademanee, A. Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant (2019) doi:10.1038/s41409-019-0694-y
  • Al Malki MM, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, Palmer J, Snyder D, Forman SJ, Nademanee A, Nakamura R. Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus/sirolimus-based GVHD prophylaxis: impact of HLA mismatch. Transplantation. 2019 Aug 19. doi: 10.1097/TP.0000000000002932. PMID: 31449184.
  • Al Malki MM, Nathwani N, Yang D, Armenian S, Dadwal S, Salman J, Mokhtari S, Cao T, Sandhu K, Rouse M, Mei M, Ali H, Parker P, Alvarnas J, Smith E, Donnell MO, Marcucci G, Snyder D, Nademanee A, Forman SJ, Stein A, Nakamura, R. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 May 9. pii:S1083-8791(18)30250-7. doi: 10.1016/j.bbmt.2018.04.029. PMID: 29753158
  • Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SO. Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 May; 24(5): 895-908. doi: 10.1016/jbbmt.2018.01.008. Epub 2018 Jan 12. PMID: 29339270
  • Al Malki MM, Aldoss I, Stiller T, Nakamura R, Snyder DS, Forman SJ, Pullarkat V. Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia Clin Lymphoma Myeloma Leuk. 2016 Jun 8. pii: S2152-2650(16)30110-0. doi: 10.1016/j.clml.2016.06.005. [Epub ahead of print]PMID:27394652

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Provider listen carefully to you
5.0
Know important info medical history
5.0
Show respect for what you say
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Spend enough time with you
4.9
Rate provider 0-10
01/28/25
Dr Al Malki continues to provide a thorough and professional care along with his staff. I am grateful for his time and attention to detail. - Verified patient
12/18/24
My doctor said I need a bone marrow transplant, I feel in the dark about what all that in tails and where it and I am in the process - Verified patient
09/20/24
100% the best. - Verified patient
09/20/24
As I said, Dr. Al Malki is a medical genuis, a fabulous doctor, and an all-around wonderful human being. - Verified patient
09/12/24
Dr Al Malki and his team saved my life, and continue to carefully treat me so that I can have the best life possible. - Verified patient